Treatment of cannabis use disorders in people with schizophrenia spectrum disorders - a systematic review
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Treatment of cannabis use disorders in people with schizophrenia spectrum disorders - a systematic review. / Hjorthøj, Carsten; Fohlmann, Allan; Nordentoft, Merete; Hjorthøj, Carsten; Fohlmann, Allan Hedegaard; Nordentoft, Merete.
I: Addictive Behaviors, Bind 34, Nr. 6-7, 2009, s. 520-5.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Treatment of cannabis use disorders in people with schizophrenia spectrum disorders - a systematic review
AU - Hjorthøj, Carsten
AU - Fohlmann, Allan
AU - Nordentoft, Merete
AU - Hjorthøj, Carsten
AU - Fohlmann, Allan Hedegaard
AU - Nordentoft, Merete
N1 - Keywords: Antipsychotic Agents; Diagnosis, Dual (Psychiatry); Humans; Marijuana Abuse; Psychotherapy; Psychotic Disorders; Research Design; Treatment Outcome
PY - 2009
Y1 - 2009
N2 - BACKGROUND: Cannabis use disorders (CUD) are prevalent among people with schizophrenia spectrum disorders (SSD), with a range of detrimental effects, e.g. reduced compliance to medication and psychosocial interventions, and increased level of psychotic-dimension symptoms. The aim of this study was to review literature on treatments of CUD in SSD-patients. METHODS: PubMed, PsycINFO, EMBASE, and The Cochrane Central Register of Controlled Trials were searched. RESULTS: 41 articles were selected, 11 treating cannabis as a separate outcome. Contingency management was only effective while active. Pharmacological interventions appeared effective, but lacked randomized controlled trials (RCTs). Psychosocial interventions, e.g. motivational interviewing and cognitive behavior therapy (CBT), were ineffective in most studies with cannabis as a separate outcome, but effective in studies that grouped cannabis together with other substance use disorders. CONCLUSIONS: Insufficient evidence exists on treating this form of dual-diagnosis patients. Studies grouping several types of substances as a single outcome may overlook differential effects. Future RCTs should investigate combinations of psychosocial, pharmacological, and contingency management.
AB - BACKGROUND: Cannabis use disorders (CUD) are prevalent among people with schizophrenia spectrum disorders (SSD), with a range of detrimental effects, e.g. reduced compliance to medication and psychosocial interventions, and increased level of psychotic-dimension symptoms. The aim of this study was to review literature on treatments of CUD in SSD-patients. METHODS: PubMed, PsycINFO, EMBASE, and The Cochrane Central Register of Controlled Trials were searched. RESULTS: 41 articles were selected, 11 treating cannabis as a separate outcome. Contingency management was only effective while active. Pharmacological interventions appeared effective, but lacked randomized controlled trials (RCTs). Psychosocial interventions, e.g. motivational interviewing and cognitive behavior therapy (CBT), were ineffective in most studies with cannabis as a separate outcome, but effective in studies that grouped cannabis together with other substance use disorders. CONCLUSIONS: Insufficient evidence exists on treating this form of dual-diagnosis patients. Studies grouping several types of substances as a single outcome may overlook differential effects. Future RCTs should investigate combinations of psychosocial, pharmacological, and contingency management.
U2 - 10.1016/j.addbeh.2009.02.001
DO - 10.1016/j.addbeh.2009.02.001
M3 - Journal article
C2 - 19268481
VL - 34
SP - 520
EP - 525
JO - Addictive Behaviors
JF - Addictive Behaviors
SN - 0306-4603
IS - 6-7
ER -
ID: 21406324